Evidence map›Paper›PMID 36982845›Full record

ArticleInternational journal of molecular sciences2023

Combined Inhibition of Hedgehog and HDAC6: In Vitro and In Vivo Studies Reveal a New Role for Lysosomal Stress in Reducing Glioblastoma Cell Viability.

Alex Pezzotta, Loredana Brioschi, Sabrina Carbone, Beatrice Mazzoleni, Vittorio Bontempi, Federica Monastra, Laura Mauri, Anna Marozzi, Marina Mione, Anna Pistocchi and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Alex PezzottaDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.ORCID 0000-0003-1788-5880
Loredana BrioschiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.
Sabrina CarboneDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.
Beatrice MazzoleniDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.
Vittorio BontempiDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.
Federica MonastraDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.
Laura MauriDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.ORCID 0000-0002-4194-4804
Anna MarozziDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.ORCID 0000-0001-9007-2590
Marina MioneDepartment of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123 Trento, Italy.ORCID 0000-0002-9040-3705
Anna PistocchiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.ORCID 0000-0001-9467-2542
Paola VianiDepartment of Medical Biotechnology and Translational Medicine, University of Milan, L.I.T.A., Via Fratelli Cervi 93, Segrate, 20054 Milano, Italy.
University of Milan · ITUniversity of Trento · IT

Funding

University of Milan DMEM, PhD program Pezzotta Alex
6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most common and malignant brain tumor in adults. The invasiveness and the rapid progression that characterize GBM negatively impact patients' survival. Temozolomide (TMZ) is currently considered the first-choice chemotherapeutic agent. Unfortunately, over 50% of patients with GBM do not respond to TMZ treatment, and the mutation-prone nature of GBM enables the development of resistance mechanisms. Therefore, efforts have been devoted to the dissection of aberrant pathways involved in GBM insurgence and resistance in order to identify new therapeutic targets. Among them, sphingolipid signaling, Hedgehog (

Indexed as

Brain NeoplasmsGlioblastomaAdultAnimalsCell Line, TumorCell SurvivalDrug Resistance, NeoplasmHedgehog ProteinsHistone Deacetylase 6HumansLysosomesSphingolipidsTemozolomideZebrafishHDAC6 protein, humanHedgehog ProteinsHistone Deacetylase 6SphingolipidsTemozolomideautophagycombination treatmentglioblastomaHDAC6Hhlysosomal stresssphingolipidszebrafish

Identifiers

PMID36982845
PMCPMC10051748
OpenAlexW4327968815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.